Clinical Trials

The purpose of this study is to quantify urologic oncology patient’s understanding of their cardiovascular health (CVH) and to evaluate how a patient’s understanding of their CVH is associated with oncologic outcomes.

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.

In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

The purpose of this study is to assess if men and women seeking care for urological diseases have interest in support services in conjunction with standard of care.